Clinical trialNCT07441642RecruitingPhase 2Interventional

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

SponsorNovartis PharmaceuticalsEnrollment272Geographic Atrophy Secondary to Age-related Macular Degeneration

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

51 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Novartis Investigative Site
Albury, New South Wales, Australia
Recruiting
Novartis Investigative Site
Parramatta, New South Wales, Australia
Recruiting
Novartis Investigative Site
Strathfield, New South Wales, Australia
Recruiting
Novartis Investigative Site
East Melbourne, Victoria, Australia
Recruiting

Bulgaria

Novartis Investigative Site
Sofia, Bulgaria
Recruiting

Canada

Novartis Investigative Site
London, Ontario, Canada
Recruiting
Novartis Investigative Site
Ottawa, Ontario, Canada
Recruiting

Czechia

Novartis Investigative Site
Prague, Czechia
Recruiting
Novartis Investigative Site
Prague, Czechia
Recruiting

France

Novartis Investigative Site
Lyon, Rhone, France
Recruiting
Novartis Investigative Site
Créteil, France
Recruiting
Novartis Investigative Site
Dijon, France
Recruiting
Novartis Investigative Site
Paris, France
Recruiting

Germany

Novartis Investigative Site
Ludwigshafen, Germany, Germany
Recruiting
Novartis Investigative Site
Bonn, Germany
Recruiting
Novartis Investigative Site
Münster, Germany
Recruiting
Novartis Investigative Site
Tübingen, Germany
Recruiting

Hungary

Novartis Investigative Site
Pécs, Baranya, Hungary
Recruiting
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Recruiting
Novartis Investigative Site
Budapest, Hungary
Recruiting

Italy

Novartis Investigative Site
Florence, FI, Italy
Recruiting
Novartis Investigative Site
Milan, MI, Italy
Recruiting
Novartis Investigative Site
Milan, MI, Italy
Recruiting
Novartis Investigative Site
Roma, RM, Italy
Recruiting

Japan

Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan
Recruiting

Poland

Novartis Investigative Site
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Recruiting
Novartis Investigative Site
Krakow, Poland
Recruiting

Puerto Rico

Emanuelli Research and Development Center Llc
Arecibo, Puerto Rico
Andres Emanuelli Anzalotta
Recruiting

Romania

Novartis Investigative Site
Cluj-Napoca, Cluj, Romania
Recruiting
Novartis Investigative Site
Bucharest, Romania
Recruiting

Spain

Novartis Investigative Site
Santiago Compostela, A Coruna, Spain
Recruiting
Novartis Investigative Site
Sant Cugat Del V, Barcelona, Spain
Recruiting
Novartis Investigative Site
Burjassot, Valencia, Spain
Recruiting
Novartis Investigative Site
Córdoba, Spain
Recruiting

United Kingdom

Novartis Investigative Site
Bristol, United Kingdom
Recruiting
Novartis Investigative Site
London, United Kingdom
Recruiting

United States

Salehi Retina Institute
Huntington Beach, California, United States
Hani Salehi-Had
Recruiting
Retinal Consultants Medical Group Inc
Sacramento, California, United States
Margaret Chang
Recruiting
California Retina Consultants
Santa Barbara, California, United States
Dante Pieramici
Recruiting
Advanced Research Llc
Boynton Beach, Florida, United States
Drew Philip Bawcombe
Recruiting

11 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

FWY003Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Mar 2026
Primary completion: 21 Aug 2029
Completion: 22 Aug 2029
Last update posted: 20 Aug 2026
Registered enrollment: 272
Registry id: NCT07441642

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.